Royce & Associates
CTSO icon

Royce & Associates’s Cytosorbents Corp CTSO Stock Holding History

Royce & Associates’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,450
Closed -$764K – 943
2022
Q2 		$764K Hold
17,450
– – 0.01% 790
2022
Q1 		$1.11M Buy
17,450
+4,900
+39% +$351K 0.01% 800
2021
Q4 		$1.05M Buy
12,550
+2,750
+28% +$309K 0.01% 799
2021
Q3 		$1.59M Buy
9,800
+2,950
+43% +$479K 0.01% 766
2021
Q2 		$1.03M Hold
6,850
– – 0.01% 847
2021
Q1 		$1.19M Hold
6,850
– – 0.01% 833
2020
Q4 		$1.09M Hold
6,850
– – 0.01% 804
2020
Q3 		$1.09M Buy
6,850
+1,000
+17% +$180K 0.01% 770
2020
Q2 		$1.16M Buy
5,850
+2,684
+85% +$493K 0.01% 755
2020
Q1 		$489K Buy
+3,166
New +$320K 0.01% 836

Other funds holding CTSO

Skylands Capital
Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return
Avenir Corporation
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Granahan Investment Management
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Sargent Investment Group
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Redmile Group
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Royce & Associates's CTSO Position: Q3 2022 in Review

Royce & Associates sold out of Cytosorbents Corp (CTSO) in Q3 2022, closing a stake of 17,450 shares — an estimated $764K sold.

Royce & Associates first reported a position in CTSO in Q1 2020 and held it in 10 quarters. The position peaked at $1.59M in Q3 2021. 60 funds tracked by Wall St. Rank hold CTSO as of Q3 2022.

  • Royce & Associates reported no remaining Cytosorbents Corp position as of Q3 2022 after selling out during the quarter.
  • Royce & Associates sold 17,450 Cytosorbents Corp shares in Q3 2022, an estimated $764K.
  • Royce & Associates first reported a position in Cytosorbents Corp in Q1 2020 and held it in 10 quarters.
  • Royce & Associates's Cytosorbents Corp position peaked at $1.59M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2022.

Based on Royce & Associates's 13F filing for Q3 2022, filed 3 Nov 2022.